Elanco Animal Health Inc
Elanco Animal Health Incorporated (NYSE: ELAN) develops and sells products and services to prevent and treat disease in pets and farm animals, serving pet owners, veterinarians, farmers, producers, distributors and retailers in more than 90 countries. It operates as a single segment, with a broad portfolio spanning… From the company’s description.
In fiscal 2025, Elanco Animal Health Inc reported revenue of $4.71B, up 6.2% from fiscal 2024, and a net loss of $232.00M. Its operating margin was 0.3%, and operations generated $560.00M in cash. Over the twelve months to Jun 30, 2026, revenue was $5.02B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Elanco Animal Health Inc does
In the company’s own words
Elanco Animal Health Incorporated (NYSE: ELAN) develops and sells products and services to prevent and treat disease in pets and farm animals, serving pet owners, veterinarians, farmers, producers, distributors and retailers in more than 90 countries. It operates as a single segment, with a broad portfolio spanning parasiticides, dermatology, vaccines and therapeutics for pets, and products for cattle, poultry, swine and sheep, including medicines, vaccines, feed additives, insecticides and enzymes. Major brands include Advantage, Seresto, Credelio, Galliprant, Zenrelia, Rumensin, Maxiban and Monteban. The company markets approximately 200 brands; its five leading products and product families together accounted for about 38% of 2025 revenue. Elanco reported approximately 9,400 full-time employees and 500 fixed-duration employees as of December 31, 2025. Its animal-health business separated from Eli Lilly and Company in 2019, and its 2020 acquisition of Bayer Animal Health expanded its portfolio and international reach. Its website is www.elanco.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- INDIANAPOLIS, IN
- Fiscal year end
- December
- CIK
- 1739104
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Elanco Animal Health Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Elanco Animal Health Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Elanco Animal Health Inc’s bonds, as funds hold them
Funds report holding 1 issues of Elanco Animal Health Inc’s debt, $299.55M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 6.40%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Elanco Animal Health Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Elanco Animal Health Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Elanco Animal Health Inc's last four quarterly filings that the numbers alone won't show?”